BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 1322791)

  • 1. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II.
    Nitiss JL; Liu YX; Harbury P; Jannatipour M; Wasserman R; Wang JC
    Cancer Res; 1992 Aug; 52(16):4467-72. PubMed ID: 1322791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine.
    Wasserman RA; Wang JC
    Cancer Res; 1994 Apr; 54(7):1795-800. PubMed ID: 8137294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide.
    Liu YX; Hsiung Y; Jannatipour M; Yeh Y; Nitiss JL
    Cancer Res; 1994 Jun; 54(11):2943-51. PubMed ID: 8187080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors.
    Nitiss JL; Liu YX; Hsiung Y
    Cancer Res; 1993 Jan; 53(1):89-93. PubMed ID: 8380128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.
    Ishida R; Hamatake M; Wasserman RA; Nitiss JL; Wang JC; Andoh T
    Cancer Res; 1995 Jun; 55(11):2299-303. PubMed ID: 7757979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine.
    Nitiss JL; Vilalta PM; Wu H; McMahon J
    Mol Pharmacol; 1994 Oct; 46(4):773-7. PubMed ID: 7969059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional expression of human topoisomerase II alpha in yeast: mutations at amino acids 450 or 803 of topoisomerase II alpha result in enzymes that can confer resistance to anti-topoisomerase II agents.
    Hsiung Y; Jannatipour M; Rose A; McMahon J; Duncan D; Nitiss JL
    Cancer Res; 1996 Jan; 56(1):91-9. PubMed ID: 8548781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
    Malik M; Nitiss KC; Enriquez-Rios V; Nitiss JL
    Mol Cancer Ther; 2006 Jun; 5(6):1405-14. PubMed ID: 16818498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
    Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
    BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
    Lelièvre S; Benchokroun Y; Larsen AK
    Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topoisomerase II-dependent and -independent mechanisms of etoposide resistance in Chinese hamster cell lines.
    Spiridonidis CA; Chatterjee S; Petzold SJ; Berger NA
    Cancer Res; 1989 Feb; 49(3):644-50. PubMed ID: 2535964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation E522K in human DNA topoisomerase IIbeta confers resistance to methyl N-(4'-(9-acridinylamino)-phenyl)carbamate hydrochloride and methyl N-(4'-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide but hypersensitivity to etoposide.
    Leontiou C; Lakey JH; Austin CA
    Mol Pharmacol; 2004 Sep; 66(3):430-9. PubMed ID: 15322234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells.
    Takano H; Kohno K; Ono M; Uchida Y; Kuwano M
    Cancer Res; 1991 Aug; 51(15):3951-7. PubMed ID: 1649696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Random mutagenesis of the B'A' core domain of yeast DNA topoisomerase II and large-scale screens of mutants resistant to the anticancer drug etoposide.
    Jiang X
    Biochem Biophys Res Commun; 2005 Feb; 327(2):597-603. PubMed ID: 15629155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
    Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
    Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine.
    Jannatipour M; Liu YX; Nitiss JL
    J Biol Chem; 1993 Sep; 268(25):18586-92. PubMed ID: 8395511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
    Holm C; Covey JM; Kerrigan D; Pommier Y
    Cancer Res; 1989 Nov; 49(22):6365-8. PubMed ID: 2553254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors.
    Tortora G; Ciardiello F; Damiano V; Pepe S; Bianco C; di Isernia G; Davies SL; North P; Harris AL; Hickson ID
    Clin Cancer Res; 1995 Jan; 1(1):49-56. PubMed ID: 9815886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity.
    Arimondo P; Boukarim C; Bailly C; Dauzonne D; Monneret C
    Anticancer Drug Des; 2000 Dec; 15(6):413-21. PubMed ID: 11716434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.